BioCentury
DATA GRAPHICS | Data Byte

Biotech stocks resume tumble

Sector leads broader market down as tariff worries persist

April 10, 2025 10:35 PM UTC

Following a short reprieve on Wednesday, biotech indexes resumed their downward fall, leading the broader markets lower as investors continued to sell off equities amid concerns about President Donald Trump’s tariff policies, including the looming threat of pharma-specific tariffs.

The SPDR S&P Biotech ETF (XBI) gave back most of its Wednesday gains as the biopharma ETF tumbled $3.27 (4%) to $71.61. The XBI had rallied 7.3% on Wednesday following Trump’s 90-day pause on most of the tariffs that had been announced just a week ago...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article